TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2004920

Group type: EXPERIMENTAL
Intervention: Heparin 4 U/ml in 0.9% sodium chloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (NSS)
Number of subjects: 30
Study: 6192514

Group type: EXPERIMENTAL
Intervention: Thromboembolic prophylaxis with dextran 70
Number of subjects: 207

Group type: COMPARATOR
Intervention: Low dose heparin combined with dihydroergotamine
Number of subjects: 207
Study: 30415637

Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids (1 g per day)
Number of subjects: 25871
Study: 30246755

Group type: EXPERIMENTAL
Intervention: Diode laser MTA pulpotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diode laser ZOE pulpotomy
Number of subjects: 40
Study: 26291629

Group type: EXPERIMENTAL
Intervention: Telephone and in‐person cognitive‐behavioral therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Revised PHQ‐9
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Revised Symptom Checklist‐20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Revised Hamilton Depression Rating Scale
Number of subjects: 100
Study: 24064511

Group type: EXPERIMENTAL
Intervention: 50 µg IC43 with adjuvant
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 100 µg IC43 with adjuvant
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 200 µg IC43 with adjuvant
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 100 µg IC43 without adjuvant
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 163
Study: 22511052

Group type: EXPERIMENTAL
Intervention: Quadruple therapy containing doxycycline (Group A): esomeprazole 20 mg, bismuth potassium citrate 220 mg, amoxicillin 1 g, doxycycline 100 mg, all bid for ten days.
Number of subjects: 85

Group type: COMPARATOR
Intervention: Routine quadruple therapy (Group B): esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, metronidazole 400 mg bid, tetracycline 750 mg q.6h, for ten days.
Number of subjects: 85
Study: 20723635

Group type: EXPERIMENTAL
Intervention: Thromboaspiration with a manual device (Export Medtronic)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 175
Study: 18436318

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15669615

Group type: EXPERIMENTAL
Intervention: Luminance and chromatic contrast matching functions (CMFs) for younger subjects
Number of subjects: 2

Group type: COMPARATOR
Intervention: Luminance and chromatic contrast matching functions (CMFs) for older subjects
Number of subjects: 2
Study: 12529345

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy immediately following surgery
Number of subjects: 477

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy until clinically indicated
Number of subjects: 477
Study: 10374092

Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment (3 cycles prior to surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preoperative treatment
Number of subjects: 60
Study: 8597266

Group type: EXPERIMENTAL
Intervention: Short-acting corticosteroid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intermediate-acting corticosteroid
Number of subjects: 12
Study: 1423177

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg orally daily for 2 years
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: PSK 3 g orally daily for 2 years
Number of subjects: 967

Group type: COMPARATOR
Intervention: Combination chemotherapy with mitomycin C (MMC) and ftorafur (FT)
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 967
Study: 6431470

Group type: EXPERIMENTAL
Intervention: Naloxone (0.7 to 1.0 micrograms/kg/min, total dose 8.8‐13.2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Haloperidol (2 mg intramuscularly before sleep onset)
Number of subjects: 8
Study: 30612807

Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP)
Number of subjects: 6679

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 6679
Study: 28478693

Group type: EXPERIMENTAL
Intervention: Controlled breathing + range of motion exercises
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Resistance exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (standard medical treatment)
Number of subjects: 90
Study: 27176615

Group type: EXPERIMENTAL
Intervention: Real rTMS (10 Hz stimulation over left dorsolateral prefrontal cortex)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 25052698

Group type: EXPERIMENTAL
Intervention: Idarubicin at a maximum-tolerated dose (MTD) of 16 mg/m² IV on day 1, combined with high-dose methotrexate (3 g/m² IV), vindesine (3 mg/m² IV), and prednisolone (60 mg/m² IV/orally) on days 1-5.
Number of subjects: 35
Study: 23082381

Group type: EXPERIMENTAL
Intervention: Alcohol‐free essential oils containing mouthrinse (Listerine Zero)
Number of subjects: 92

Group type: COMPARATOR
Intervention: 5% hydroalcohol negative control rinse
Number of subjects: 92
Study: 20719450

Group type: EXPERIMENTAL
Intervention: Rosemary extract plus vitamin E and omega-3 PUFAs added to standard diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet without rosemary extract, vitamin E, and omega-3 PUFAs
Number of subjects: 0
Study: 18757472

Group type: EXPERIMENTAL
Intervention: Biaxial microincision cataract surgery (B‐MICS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coaxial small‐incision cataract surgery (C‐SICS)
Number of subjects: 30
Study: 15627809

Group type: EXPERIMENTAL
Intervention: Slow-release caffeine (SRC) 300 mg twice a day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12435461

Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2mg/kg bolus for 5 min followed by 2mg/kg/h infusion for 40 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cumulative doses of systemic lidocaine (0.5-2mg/kg) injected 30 min after incision
Number of subjects: 16
Study: 10491676

Group type: EXPERIMENTAL
Intervention: CCNW plan
Number of subjects: 251

Group type: COMPARATOR
Intervention: Usual-care diet
Number of subjects: 251
Study: 8086649

Group type: EXPERIMENTAL
Intervention: Health test and health conversations in general practice
Number of subjects: 898

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 898
Study: 2456626

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 36
Study: 29735963

Group type: EXPERIMENTAL
Intervention: Acupuncture plus hydrotherapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 27955807

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRGF)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard cure with saline (Control)
Number of subjects: 58
Study: 25043647

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (a nitric oxide donor) given for seven days
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Continuing pre-stroke antihypertensive therapy
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No glyceryl trinitrate
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Stopping (temporarily for seven days) pre-stroke antihypertensive drugs
Number of subjects: 4011
Study: 23116438

Group type: EXPERIMENTAL
Intervention: Cemex Rx bone cement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Palacos R bone cement
Number of subjects: 44
Study: 20044997

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Electrogalvanic stimulation (EGS)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (possible LAS)
Number of subjects: 157
Study: 18485457

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 16 mg lornoxicam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 60
Study: 16401155

Group type: EXPERIMENTAL
Intervention: High-dose divalproex
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose divalproex
Number of subjects: 71
Study: 12771535

Group type: EXPERIMENTAL
Intervention: High-flux dialyzers (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration
Number of subjects: 125

Group type: COMPARATOR
Intervention: Low-flux dialyzers (polysulfone or cellulose triacetate membranes)
Number of subjects: 125
Study: 10232740

Group type: EXPERIMENTAL
Intervention: Autologous BMT recipients
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Histocompatible BMT recipients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Unrelated BMT recipients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Histocompatible BMT recipients >3 years post-BMT
Number of subjects: 54
Study: 8610383

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 800 mg q 8 hr for at least 24 h
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF)
Number of subjects: 46
Study: 1467165

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIV) of morphine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intermittent parenteral opioids (IPO)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oxygen inhalation (50% O2)
Number of subjects: 66
Study: 6369238

Group type: EXPERIMENTAL
Intervention: Phenobarbital treatment (two loading doses of 10 mg/kg 12 hours apart, followed by a maintenance dose of 2.5 mg/kg every 12 hours for 6 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 31655812

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study: 29765213

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily add-on therapy
Number of subjects: 3274
Study: 27281722

Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 99
Study: 24322216

Group type: EXPERIMENTAL
Intervention: Self-selected position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Other positions (including crucifix-type position)
Number of subjects: 20
Study: 22249013

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CA)
Number of subjects: 66
Study: 20228999

Group type: EXPERIMENTAL
Intervention: Propofol continuous infusion (0.8 mg/kg induction dose and 3 mg/kg/h maintenance dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent midazolam injection (mean total dose 10.3 +/- 4.5 mg)
Number of subjects: 60
Study: 17410104

Group type: EXPERIMENTAL
Intervention: Furosemide and fludrocortisone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ammonium chloride
Number of subjects: 21
Study: 15602505

Group type: EXPERIMENTAL
Intervention: Low-dose liquid fluoxetine (mean final dose: 9.9±4.35 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Liquid fluoxetine
Number of subjects: 45
Study: 11943041

Group type: EXPERIMENTAL
Intervention: Leg power
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Leg strength
Number of subjects: 45
Study: 10194869

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 0
Study: 7598779

Group type: EXPERIMENTAL
Intervention: Hypertonic hydrogel with polyurethane secondary dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline moistened gauze (wet-to-dry technique)
Number of subjects: 0
Study: 2030849

Group type: EXPERIMENTAL
Intervention: Closure of both the visceral and parietal peritoneum with absorbable suture (N = 59)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No peritoneal closure (N = 54)
Number of subjects: 113
Study: 6760183

Group type: EXPERIMENTAL
Intervention: VCAD protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: COMP protocol
Number of subjects: 10
Study: 31141288

Group type: EXPERIMENTAL
Intervention: Slow loaded breathing training (SLB): 25% maximum inspiratory pressure, 6 breaths per minute, 60 breaths every day for 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Slow loaded breathing training (SLB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deep breathing control (CON)
Number of subjects: 20
Study: 27502323

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) guided by the 15-gene expression signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) guided by clinical stage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of the 15-gene expression signature
Number of subjects: 0
Study: 25727713

Group type: EXPERIMENTAL
Intervention: 2- to 5-day PLTs
Number of subjects: 122

Group type: COMPARATOR
Intervention: 6- or 7-day PLTs
Number of subjects: 122
Study: 24502891

Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling in women with PCOS
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling in women with IGT at baseline (n = 6)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Peripheral venous blood sampling in healthy controls
Number of subjects: 129

Group type: COMPARATOR
Intervention: Peripheral venous blood sampling in healthy controls with IGT at baseline (n = 3)
Number of subjects: 129
Study: 22519750

Group type: EXPERIMENTAL
Intervention: Smoking-specific communication
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Parental smoking
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Frequency of communication
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Quality of communication
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Pro-smoking attitudes
Number of subjects: 1478
Study: 20716074

Group type: EXPERIMENTAL
Intervention: Insufflation (Group I)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Intubation/awake extubation (Group A)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Intubation/deep extubation (Group D)
Number of subjects: 415
Study: 17953678

Group type: EXPERIMENTAL
Intervention: Neutral pH superoxidised aqueous solution (NpHSS)
Number of subjects: 45
Study: 16288379

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 528
Study: 12429535

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment starting at 7.5 mg/week, increased to a maximum of 25 mg/week if necessary
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 103
Study: 9449399

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8586074

Group type: EXPERIMENTAL
Intervention: Sandpaper handle with 4.2 kg load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smooth aluminum handle with 4.2 kg load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sandpaper handle with lower loads (0.8 kg and 2.5 kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smooth aluminum handle with lower loads (0.8 kg and 2.5 kg)
Number of subjects: 10
Study: 2121507

Group type: EXPERIMENTAL
Intervention: Monounsaturated diet (15.1% energy from monounsaturated and 7.9% from polyunsaturated fatty acids)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Polyunsaturated fatty acid-enriched diet (10.8% from monounsaturated and 12.7% from polyunsaturated fatty acids)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control diet (19.3% of energy as saturated fat)
Number of subjects: 58
Study: 402671

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (imipramine and amitriptyline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (baseline prolactin levels)
Number of subjects: 0
Study: 31267573

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 530
Study: 29070160

Group type: EXPERIMENTAL
Intervention: Ca3SiO5-based dentin substitute
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ca(OH)2-based liner
Number of subjects: 80
Study: 24770382

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with modified bone-patellar tendon-bone (BPTB) allograft
Number of subjects: 94

Group type: COMPARATOR
Intervention: Double-bundle ACL reconstruction with tibialis anterior allograft
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with modified BPTB allograft
Number of subjects: 94
Study: 23889217

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in young women under 40 years
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (3 tablets daily of 25 mg micronized DHEA for at least 12 weeks) in women over 40 years
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (24 women over 40 years not treated with DHEA)
Number of subjects: 77
Study: 23080088

Group type: EXPERIMENTAL
Intervention: Bare Metal Stent (BMS) - Chopin II(TM), Balton, Poland
Number of subjects: 111

Group type: COMPARATOR
Intervention: Drug Eluting Stent (DES) - Paclitaxel eluting stent (Chopin Luc(TM), Balton, Poland)
Number of subjects: 111
Study: 19032573

Group type: EXPERIMENTAL
Intervention: Nicotine (0.5 mg/kg s.c.) administered via 10 injections every second day starting from postnatal day 27 for adolescents and day 75 for adults.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine (0.5 mg/kg) administered to challenge animals after initial treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, but comparisons made between adolescent and adult rats.
Number of subjects: 0
Study: 17465948

Group type: EXPERIMENTAL
Intervention: Blood Conservation Algorithm (BCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study: 15009842

Group type: EXPERIMENTAL
Intervention: Azithromycin (5-days treatment)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Metronidazole (7-days treatment)
Number of subjects: 25
Study: 11152432

Group type: EXPERIMENTAL
Intervention: Single dose of azithromycin (1.5 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 3 day regimen of azithromycin (500 mg/day)
Number of subjects: 12
Study: 9471423

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms subcutaneously, three times daily for two days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7952561

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis (TAP) with tobramycin, colistin, and amphotericin B administered in oropharynx and stomach.
Number of subjects: 97

Group type: COMPARATOR
Intervention: No topical antimicrobial prophylaxis (Control Group 2).
Number of subjects: 97

Group type: COMPARATOR
Intervention: No topical antimicrobial prophylaxis (Control Group 3).
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis (TAP) (Group 1).
Number of subjects: 97
Study: 3608351

Group type: EXPERIMENTAL
Intervention: 25 mg intravenous trazodone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 50 mg oral trazodone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Obese subjects (mean weight 112 kg)
Number of subjects: 43
Study: 30425247

Group type: EXPERIMENTAL
Intervention: Low-gluten diet (2 g gluten per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-gluten diet (18 g gluten per day)
Number of subjects: 60
Study: 27076370

Group type: EXPERIMENTAL
Intervention: Lidocaine (intravenous bolus of 1.5 mg/kg at induction of anesthesia, followed by an infusion of 1.5 mg · kg · h until 30 minutes after PACU arrival)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25147326

Group type: EXPERIMENTAL
Intervention: Target systolic BP <150 mm Hg (n=37; SBP 140±18 mm Hg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Target systolic BP <180 mm Hg (n=36; SBP 162±12 mm Hg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Target systolic BP <150 mm Hg (n=37)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Target systolic BP <180 mm Hg (n=36)
Number of subjects: 75
Study: 22251024

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other sleep medications
Number of subjects: 0
Study: 20674640

Group type: EXPERIMENTAL
Intervention: Walking (moderate-intensity for approximately 40 min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 19
Study: 18399256

Group type: EXPERIMENTAL
Intervention: Oral immunonutrition (Impact Oral) for 7-10 days before surgery
Number of subjects: 153

Group type: COMPARATOR
Intervention: No nutritional support
Number of subjects: 153

Group type: COMPARATOR
Intervention: Normal group (without malnutrition)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Serum albuminemia <2.8 gr/dl
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lymphocyte count <1.500 mm3
Number of subjects: 153
Study: 16036166

Group type: EXPERIMENTAL
Intervention: Histamine 10(-2)M
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Histamine 10(-22)M
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water controls
Number of subjects: 7
Study: 11837826

Group type: EXPERIMENTAL
Intervention: Gotfried percutaneous compression plate (PCCP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Classic hip screw (CHS)
Number of subjects: 111
Study: 10066840

Group type: EXPERIMENTAL
Intervention: Nadroparin (180 anti-factor Xa units/kg per 24 hours) for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nadroparin (180 anti-factor Xa units/kg per 24 hours) for 3 weeks followed by oral anticoagulants for 3 months
Number of subjects: 60
Study: 7717368

Group type: EXPERIMENTAL
Intervention: Decision board
Number of subjects: 42

Group type: COMPARATOR
Intervention: Short version of the instrument
Number of subjects: 42